Marine Compounds and Cancer 2020

doi:10.3390/books978-3-0365-0631-9

dc.contributor.editor	Honecker, Friedemann
dc.contributor.editor	Dyshlovoy, Sergey A.
dc.date.accessioned	2022-01-11T13:31:23Z
dc.date.available	2022-01-11T13:31:23Z
dc.date.issued	2021
dc.identifier	ONIX_20220111_9783036506302_154
dc.identifier.uri	https://directory.doabooks.org/handle/20.500.12854/76418
dc.description.abstract	The very first marine-derived anticancer drug, Cytarabine (aka Ara-C, Cytosar-U®), was approved by the FDA in 1969 for the treatment of leukemia. At the beginning of 2021, the list of approved marine-derived anticancer drugs consists of nine substances, five of which received approval within the last two years, demonstrating the rapid evolution of the field. The current book is a collection of scientific articles related to the exponentially growing field of anticancer marine compounds. These articles cover the whole field, from agents with cancer-preventive activity, to novel and previously characterized compounds with anticancer activity, both in vitro and in vivo, as well as the latest status of compounds under clinical development.
dc.language	English
dc.subject.classification	thema EDItEUR::M Medicine and Nursing	en_US
dc.subject.other	apoptosis
dc.subject.other	fucoidan
dc.subject.other	hepatocellular carcinoma
dc.subject.other	reactive oxygen species
dc.subject.other	3-alkylpyridinium polymers
dc.subject.other	nicotine
dc.subject.other	nicotinic acetylcholine receptor
dc.subject.other	non-small cell lung carcinoma
dc.subject.other	melanoma
dc.subject.other	sinulariolide
dc.subject.other	proteomic
dc.subject.other	mitochondria
dc.subject.other	caspase cascade
dc.subject.other	marine fungus
dc.subject.other	sediment
dc.subject.other	anthranilic acid
dc.subject.other	Penicillium paneum
dc.subject.other	cytotoxicity
dc.subject.other	dibromotyrosine
dc.subject.other	mitochondrial dysfunction
dc.subject.other	oxidative stress
dc.subject.other	topoisomerase
dc.subject.other	epigonal organ
dc.subject.other	bonnethead shark
dc.subject.other	Jurkat
dc.subject.other	tumor cell line
dc.subject.other	hippuristanol
dc.subject.other	PEL
dc.subject.other	AP-1
dc.subject.other	STAT3
dc.subject.other	Akt
dc.subject.other	colorectal cancer
dc.subject.other	marine mollusc
dc.subject.other	brominated indoles
dc.subject.other	shrimp
dc.subject.other	chemoprevention
dc.subject.other	fatty acids
dc.subject.other	carotenoids
dc.subject.other	cancer
dc.subject.other	nanoparticle
dc.subject.other	osteosarcoma
dc.subject.other	lung metastasis
dc.subject.other	elisidepsin
dc.subject.other	lipid rafts
dc.subject.other	hydroxylated lipids
dc.subject.other	fatty acid 2-hydroxylase
dc.subject.other	cooperative binding
dc.subject.other	membrane permeabilization
dc.subject.other	marine organisms
dc.subject.other	polysaccharides
dc.subject.other	anticancer
dc.subject.other	anticarcinogenic
dc.subject.other	mechanisms of action
dc.subject.other	fumigaclavine C
dc.subject.other	anti-proliferation
dc.subject.other	mitochondrial pathway
dc.subject.other	anti-cancer
dc.subject.other	anti-proliferative
dc.subject.other	carotenoid
dc.subject.other	cell cycle arrest
dc.subject.other	fucoxanthin
dc.subject.other	azoxymethane
dc.subject.other	bioactive natural product
dc.subject.other	isatin
dc.subject.other	in vivo model
dc.subject.other	Marthasterias glacialis L.
dc.subject.other	palmitic acid
dc.subject.other	ER-stress
dc.subject.other	CHOP
dc.subject.other	Antibody Drug Conjugates (ADCs)
dc.subject.other	marine antitumor agents
dc.subject.other	clinical trials
dc.subject.other	approved antitumor agents
dc.subject.other	AD0157
dc.subject.other	angiogenesis
dc.subject.other	marine drug
dc.subject.other	pyrrolidinedione
dc.subject.other	secondary metabolites
dc.subject.other	cancer preventive
dc.subject.other	chemopreventive
dc.subject.other	trabectedin
dc.subject.other	plitidepsin
dc.subject.other	tumor-associated macrophages
dc.subject.other	tumor microenvironment
dc.subject.other	preclinical
dc.subject.other	anticancer immunity
dc.subject.other	antiangiogenesis
dc.subject.other	fascaplysin
dc.subject.other	cyclin-dependent kinase
dc.subject.other	small cell lung cancer
dc.subject.other	camptothecin
dc.subject.other	poly(ADP-ribose)-polymerase inhibitor
dc.subject.other	breast cancer
dc.subject.other	seaweed
dc.subject.other	therapeutic compounds
dc.subject.other	autophagy
dc.subject.other	marine drugs
dc.subject.other	autophagy inhibitors
dc.subject.other	autophagy inducers
dc.subject.other	macrolide
dc.subject.other	programmed cell death
dc.subject.other	energy stress
dc.subject.other	araguspongine C
dc.subject.other	c-Met
dc.subject.other	HER2
dc.subject.other	gemcitabine
dc.subject.other	pazopanib
dc.subject.other	phase I
dc.subject.other	safety
dc.subject.other	soft tissue sarcoma
dc.subject.other	pachastrissamine
dc.subject.other	jaspine B
dc.subject.other	carbocyclic analogue
dc.subject.other	sphingosine kinase inhibitor
dc.subject.other	molecular modeling
dc.subject.other	ET-743
dc.subject.other	DNA minor groove binder
dc.subject.other	soft tissue sarcoma
dc.subject.other	chemotherapy
dc.subject.other	bis (2,3-dibromo-4,5-dihydroxy-phenyl)-methane (BDDPM)
dc.subject.other	anti-metastatic activity
dc.subject.other	cell adhesion
dc.subject.other	β1-integrin
dc.subject.other	FAK
dc.subject.other	BEL-7402 cell
dc.subject.other	triterpene glycosides
dc.subject.other	sea cucumbers
dc.subject.other	antitumor activities
dc.subject.other	arrest of cell cycle
dc.subject.other	antibacterial
dc.subject.other	marangucyclines
dc.subject.other	deep-sea
dc.subject.other	Streptomyces sp. SCSIO 11594
dc.subject.other	LS-1
dc.subject.other	SNU-C5/5-FU
dc.subject.other	TGF-β signaling
dc.subject.other	carcinoembryonic antigen
dc.subject.other	kalkitoxin
dc.subject.other	Moorea producens
dc.subject.other	mitochondria toxin
dc.subject.other	VEGF
dc.subject.other	angiogenesis inhibitor
dc.subject.other	hypoxia-inducible factor-1
dc.subject.other	HIF-1
dc.subject.other	Lyngbya majuscula
dc.subject.other	marine metabolites
dc.subject.other	SZ-685C
dc.subject.other	nonfunctioning pituitary adenomas
dc.subject.other	Ecklonia cava
dc.subject.other	phlorotannins
dc.subject.other	dieckol
dc.subject.other	migration
dc.subject.other	sipholenol A
dc.subject.other	ABC transporter
dc.subject.other	multidrug resistance
dc.subject.other	P-gp/ABCB1
dc.subject.other	BCRP/ABCG2
dc.subject.other	MRP1/ABCC1
dc.subject.other	marine natural products
dc.subject.other	glioblastoma
dc.subject.other	xyloketal B
dc.subject.other	proliferation
dc.subject.other	TRPM7
dc.subject.other	marine compound
dc.subject.other	ribosomal protein genes
dc.subject.other	snoRNA
dc.subject.other	FAU
dc.subject.other	RPS30
dc.subject.other	SNORA62
dc.subject.other	evolution
dc.subject.other	Porifera
dc.subject.other	n/a
dc.subject.other	Penicillium brevicompactum
dc.subject.other	Brevianamide
dc.subject.other	Mycochromenic acid derivative
dc.subject.other	antifouling
dc.subject.other	Caribbean sponge
dc.subject.other	plakortide
dc.subject.other	endoperoxide
dc.subject.other	leukemia
dc.subject.other	multi-drug resistant leukemia
dc.subject.other	Sarcophyton ehrenbergi
dc.subject.other	soft coral
dc.subject.other	terpenes
dc.subject.other	cembranoids
dc.subject.other	cytotoxic activity
dc.subject.other	molecular docking
dc.subject.other	uveal melanoma
dc.subject.other	oxidative stress
dc.subject.other	virtual screening
dc.subject.other	Topo I inhibitor
dc.subject.other	low toxic
dc.subject.other	natural product
dc.subject.other	Ulva fasciata
dc.subject.other	selenium-containing polysaccharide-protein complex
dc.subject.other	pseudopterosin
dc.subject.other	NF-κB
dc.subject.other	p65
dc.subject.other	inflammation
dc.subject.other	cytokine release
dc.subject.other	IL-6
dc.subject.other	TNFα
dc.subject.other	MCP-1
dc.subject.other	glucocorticoid receptor
dc.subject.other	paulomycins
dc.subject.other	Micromonospora
dc.subject.other	antitumor
dc.subject.other	Cantabrian Sea-derived actinobacteria
dc.subject.other	puupehenones
dc.subject.other	sponges
dc.subject.other	antiangiogenic
dc.subject.other	antitumoral
dc.subject.other	porifera/sponge
dc.subject.other	cancer genes
dc.subject.other	molecular oncology
dc.subject.other	bromophenol
dc.subject.other	molecular mechanisms
dc.subject.other	cell cycle
dc.subject.other	PI3K/Akt
dc.subject.other	p38/ERK
dc.subject.other	ROS
dc.subject.other	human lung cancer
dc.subject.other	glycosaminoglycans
dc.subject.other	antiproliferative
dc.subject.other	heparan sulphate
dc.subject.other	gliotoxin
dc.subject.other	NSCLC
dc.subject.other	adriamycin resistance
dc.subject.other	Sepia ink polysaccharides
dc.subject.other	antitumour
dc.subject.other	chemosensitization
dc.subject.other	anticoagulation
dc.subject.other	sea anemone
dc.subject.other	drug discovery
dc.subject.other	endothelial cells
dc.subject.other	RGD motif
dc.subject.other	kunitz type inhibitor
dc.subject.other	prostate cancer
dc.subject.other	antioxidant
dc.subject.other	natural marine compounds
dc.subject.other	marine biotechnology
dc.subject.other	microalgae
dc.subject.other	marine sponges
dc.subject.other	Aeroplysinin
dc.subject.other	Isofistularin
dc.subject.other	pheochromocytoma and paraganglioma
dc.subject.other	metastasis
dc.subject.other	cancer progression
dc.subject.other	cell adhesion molecules
dc.subject.other	integrin β1
dc.subject.other	hypoxia
dc.subject.other	phycocyanin
dc.subject.other	non-small cell lung cancer
dc.subject.other	NF-κB signaling
dc.subject.other	marine-derived drugs
dc.subject.other	bioanalysis
dc.subject.other	chromatography
dc.subject.other	manzamine A
dc.subject.other	epithelial–mesenchymal transition
dc.subject.other	lung cancer
dc.subject.other	circulating tumor cells
dc.subject.other	signal transduction
dc.subject.other	cisplatin
dc.subject.other	Lampetra morii
dc.subject.other	buccal gland
dc.subject.other	cystatin F
dc.subject.other	anti-angiogenesis
dc.subject.other	cystatin superfamily
dc.subject.other	Antimicrobial peptide (AMP)
dc.subject.other	Tilapia piscidin 4 (TP4)
dc.subject.other	non-small cell lung cancer (NSCLC)
dc.subject.other	itampolin A
dc.subject.other	FBDD
dc.subject.other	p38α
dc.subject.other	novel inhibitor
dc.subject.other	tetracenomycin X
dc.subject.other	cyclin D1
dc.subject.other	proteasomal degradation
dc.subject.other	p38
dc.subject.other	c-JUN
dc.subject.other	λ-carrageenan
dc.subject.other	heparanase
dc.subject.other	anticoagulant
dc.subject.other	depolymerisation
dc.subject.other	cell migration
dc.subject.other	Aspergillus
dc.subject.other	naphthopyrones
dc.subject.other	endophytic fungus
dc.subject.other	Leathesia nana
dc.subject.other	mangrove-derived actinomycete
dc.subject.other	ansamycins
dc.subject.other	divergolides
dc.subject.other	apoptosis-inducing activity
dc.subject.other	actinomycin
dc.subject.other	EMT
dc.subject.other	invasion
dc.subject.other	low molecular weight fucoidan extract
dc.subject.other	N-Ras
dc.subject.other	neuroblastoma-rat sarcoma
dc.subject.other	Cancer
dc.subject.other	programmed cell death-ligand 1
dc.subject.other	programmed cell death-ligand 2
dc.subject.other	human sarcoma cell line (HT1080 cells)
dc.subject.other	human normal diploid fibroblast (TIG-1 cells)
dc.subject.other	chimera
dc.subject.other	chemical conjugation
dc.subject.other	anticancer agent
dc.subject.other	hybridization
dc.subject.other	α9-nicotinic acetylcholine receptors (nAChRs)
dc.subject.other	breast cancer cells
dc.subject.other	αO-conotoxin GeXIVA
dc.subject.other	targeted therapy
dc.subject.other	gorgonian
dc.subject.other	Leptogorgia
dc.subject.other	humulane sesquiterpenoids
dc.subject.other	anticancer activity
dc.subject.other	12-deacetyl-12-epi-scalaradial
dc.subject.other	HeLa cells
dc.subject.other	Nur77
dc.subject.other	MAPK/ERK pathway
dc.subject.other	Mycalin A
dc.subject.other	C15 acetogenins
dc.subject.other	synthetic analogues
dc.subject.other	antiproliferative activity
dc.subject.other	A375 and HeLa cell lines
dc.subject.other	polyoxygenated steroids
dc.subject.other	sponge
dc.subject.other	Haliclona gracilis
dc.subject.other	Thalassia testudinum
dc.subject.other	thalassiolin B
dc.subject.other	polyphenols
dc.subject.other	CYP1A1
dc.subject.other	benzo[a]pyrene
dc.subject.other	JNK1/2
dc.subject.other	natural products
dc.subject.other	synergism
dc.subject.other	A549 cells
dc.subject.other	cytoskeleton
dc.subject.other	P2X7 receptor
dc.subject.other	pollution
dc.subject.other	anti-angiogenic
dc.subject.other	gene expression
dc.subject.other	HSP90
dc.subject.other	inhibitor
dc.title	Marine Compounds and Cancer 2020
dc.type	book
oapen.identifier.doi	10.3390/books978-3-0365-0631-9
oapen.relation.isPublishedBy	46cabcaa-dd94-4bfe-87b4-55023c1b36d0
oapen.relation.isbn	9783036506302
oapen.relation.isbn	9783036506319
oapen.pages	480
oapen.place.publication	Basel, Switzerland

Fichier(s) constituant ce document

Fichiers	Taille	Format	Vue
Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Imported or submitted locally

Afficher la notice abrégée

Excepté là où spécifié autrement, la license de ce document est décrite en tant que https://creativecommons.org/licenses/by/4.0/